Table 2

Timing of measurements and outline of primary and secondary outcome measures

0 m
B.A.
 3 m
Q
 6 m
Visit
 9 m
Q
 12 m
Visit
 15 m
Q
 18 m
Visit
 21 m
Q
 24 m
F.A.
Primary outcome measures








Joint space width
 x






x
Pain score (WOMAC)
 x






x
Function score (WOMAC)
 x






x










Secondary outcome measures








Subchondral bone quality
 x






x
Stiffness score (WOMAC)
 x
 x
 x
 x
 x
 x
 x
 x
 x
Quality of life (EuroQol EQ-5D)
 x
 x
 x
 x
 x
 x
 x
 x
 x
Medical consumption
 x
 x
 x
 x
 x
 x
 x
 x
 x
Side effects
x
 x
 x
 x
 x
 x
 x
 x
CTX-II
 x
x
x
x
x










Possible confounders/Effect modifiers








Type of OA (localised – generalised)
 x







Radiological severity
 x






x
Joint function
 x






x
Age
 x







Gender
 x







Activity level
 x
 x
 x
 x
 x
 x
 x
 x
 x
Co-interventions
 x
 x
 x
 x
 x
 x
 x
 x
 x
Compliance (BMQ)
x
 x
 x
 x
 x
 x
 x
 x
Compliance (pill count)

x
x
x
x

Note: 0 m: 0 month of follow up, 3 m: 3 months of follow up etc. B.A.: baseline assessment. Visit: 6 monthly visit. F.A.: final assessment

Rozendaal et al. BMC Musculoskeletal Disorders 2005 6:20   doi:10.1186/1471-2474-6-20